Now showing items 1-4 of 4

    • Returns to R&D on new drug introductions in the 1980s. 

      Grabowski, HG; Vernon, JM (J Health Econ, 1994-12)
      This study finds that the mean IRR for 1980-84 U.S. new drug introductions is 11.1%, and the mean NPV is 22 million (1990 dollars). The distribution of returns is highly skewed. The results are robust to plausible changes ...
    • The distribution of sales revenues from pharmaceutical innovation. 

      Grabowski, HG; Vernon, J (Pharmacoeconomics, 2000)
      OBJECTIVE: This report updates our earlier work on the returns to pharmaceutical research and development (R&D) in the US (1980 to 1984), which showed that the returns distributions are highly skewed. It evaluates a more ...
    • The price of innovation: new estimates of drug development costs. 

      DiMasi, Joseph A; Hansen, Ronald W; Grabowski, Henry G (J Health Econ, 2003-03)
      The research and development costs of 68 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms. These data were used to estimate the average pre-tax cost of new drug development. The costs of ...
    • The quantity and quality of worldwide new drug introductions, 1982-2003. 

      Grabowski, Henry G; Wang, Y Richard (Health Aff (Millwood), 2006-03)
      We examined trends in the introduction of new chemical entities (NCEs) worldwide from 1982 through 2003. Although annual introductions of NCEs decreased over time, introductions of high-quality NCEs (that is, global and ...